
As regulatory authorities crack down on data integrity violations, bio/pharma companies must ensure adequate data governance programs are in place.
Ron George, PhD, is director of Science and Technology at Lachman Consultants, r.george@lachmanconsultants.com

As regulatory authorities crack down on data integrity violations, bio/pharma companies must ensure adequate data governance programs are in place.

Data governance is necessary for compliance with current regulatory expectations for data integrity in pharmaceutical R&D and manufacturing organizations.

Published: November 2nd 2017 | Updated:

Published: December 6th 2017 | Updated: